SuperGen comments on preliminary efficacy update on EORTC phase 3 trial of Dacogen(R) versus supportive care i DUBLIN, Calif.- SuperGen Inc.
(NASDAQ:SUPG) , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today commented on the preliminary...
Celgene Savors the Schadenfreude In the pharmaceutical world, the failure of a competitor's drug can be just as lucrative as your own compound's success.Shares of Celgene (Nasdaq: CELG) will likely enjoy this phenomenon, after its No.
3 drug, Vidaza, got a competitive...
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Pa WOODCLIFF LAKE, N.J.Subsequent to database lock and the completion of data analysis, comprehensive results of the study, including secondary efficacy endpoints and safety data, will be presented by EORTC at an upcoming scientific forum.
Analyst: European Approval Unlikely Dacogen Failure in MDS Phase III Offers Boost to Celgene's Vidaza Byline: Jennifer Boggs, Assistant Managing Editor Long-awaited survival data for Dacogen (decitabine) failed to show a significant survival advantage compared to best supportive care in patients with myelodysplastic syndromes, sending...
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care i DUBLIN, Calif.Subsequent to database lock and the completion of data analysis, comprehensive results of the study, including secondary efficacy endpoints and safety data, will be presented by EORTC at an upcoming scientific forum.
2008...
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Pa /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive Care (BSC) in elderly patients with myelodysplastic...
SuperGen drug fails trial; likely delay to European nod BANGALORE (Reuters) - SuperGen Inc said preliminary efficacy data from a late-stage trial of its blood-disorder treatment failed to meet its main goal, potentially delaying European approval of the drug and sending its shares down 15 percent...
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Pa Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008 WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002...
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Pa Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008 WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002...
Celgene rises as rival SuperGen's bone marrow cancer drug fails late stage European study - 6:43 p.m.NEW YORK (AP) - Shares of biotechnology company Celgene Corp.
advanced Tuesday as a potential competitor to its bone-marrow cancer treatment in Europe failed a late-stage clinical trial.
Celgene shares rose $5.39, or 8.4...
Celgene Shares Rise As Rival SuperGens Bone Marrow Cancer Drug Fails Late-Stage Study (FinancialWire) Shares of biotechnology company Celgene Corp.(NASDAQ: CELG) rose as SuperGen Inc.
(NASDAQ: SUPG), a potential competitor, to its bone-marrow cancer treatment in Europe failed a late-stage clinical trial.
SuperGen said...
SuperGen shares slide on late-stage Dacogen failure Shares of SuperGen took a dive this morning after the company revealed that Dacogen failed a late-stage trial for the bone marrow disease MDS.Researchers say the drug failed to improve the median survival rate of patients when...
MGI Pharma Inc - SWOT Analysis - New Research Report on Companies and Markets Company-Profile/MGI-Pharma-I ..MGI Pharma Inc Company Profile is the essential source for top-level company data and information.
The report examines the company's key business structure and operations, history and products, and...
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care i DUBLIN, Calif.Subsequent to database lock and the completion of data analysis, comprehensive results of the study, including secondary efficacy endpoints and safety data, will be presented by EORTC at an upcoming scientific forum.
2008...
Celgene Shares Rise As Rival SuperGen's Bone Marrow Cancer Drug Fails Late-Stage Study (FinancialWire) Shares of biotechnology company Celgene Corp.(NASDAQ: CELG) rose as SuperGen Inc.
(NASDAQ: SUPG), a potential competitor, to its bone-marrow cancer treatment in Europe failed a late-stage clinical trial.
SuperGen said...
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Pa /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive Care (BSC) in elderly patients with myelodysplastic...
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care i DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- SuperGen Inc., a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today commented on...
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen Versus Supportive Care in Patie Submission of Five-Day Dosing Regimen sNDA Targeted for Fiscal Year-end 2008 WOODCLIFF LAKE, N.J., July 01, 2008, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in...
SuperGen's shares fall on Phase III results for Dacogen in patients with MDS SuperGen announced Tuesday that preliminary late-stage trial data of Dacogen (decitabine) injection indicated that the drug did not significantly improve median survival in elderly patients with myelodysplastic syndromes (MDS),...
A Negative for SuperGen, a Plus for Celgene Anticancer company SuperGen SUPG said Tuesday that its Dacogen failed a late-stage trial in patients with myelodysplastic syndromes (MDS) -- news that may lend advantage to competitor Celgene's CELG Vidaza, which will be relaunched...
[external] A Negative for SuperGen, a Plus for Celgene Anticancer company SuperGen SUPG said Tuesday that its Dacogen failed a late-stage trial in patients with myelodysplastic syndromes (MDS) -- news that may lend advantage to competitor Celgene's CELG Vidaza, which will be relaunched...
A Negative for SuperGen, a Plus for Celgene Anticancer company SuperGen SUPG said Tuesday that its Dacogen failed a late-stage trial in patients with myelodysplastic syndromes (MDS) -- news that may lend advantage to competitor Celgene's CELG Vidaza, which will be relaunched...
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen Versus Supportive Care in P Reiterates 2008 Annual Financial Guidance DUBLIN, Calif., July 01, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc., a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors...
Celgene shares rise as rival's drug fails study NEW YORK (AP) -- Shares of biotechnology company Celgene Corp.advanced Tuesday as a potential competitor to its bone-marrow cancer treatment in Europe failed a late-stage clinical trial.Celgene shares rose $2.27, or 3.6 percent, to $66.14...
SuperGen Bust a Boon for Celgene (Update) Anticancer company SuperGen SUPG said Tuesday that its Dacogen failed a late-stage trial in patients with myelodysplastic syndromes (MDS) -- news that may lend advantage to competitor Celgene's CELG Vidaza, which will be relaunched...
